ClinicalTrials.gg
RecruitingNCT06907667CHRONOVAX2Updated May 15, 2026

Study of the Impact of Time of Vaccination on Response to Influenza Vaccine in Patients With Chronic Renal Failure

An interventional study of Vaccine injection in Vaccination; Infection, sponsored by Centre Hospitalier Universitaire de Nice. Recruiting at 1 site in France. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-05-15.

Primary conditionInfluenza, HumanRegistry: InfectionsReclassifiedWhy we changed it
Registry
Infections — the first condition term the registry derived for this study.
ClinicalTrials.gg
Influenza, Human
Why
  1. The study's title name Influenza, Human, a narrower term within Infections.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Centre Hospitalier Universitaire de Nice · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
735
Allocation
Randomized
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 103 studies in Influenza, Human with a site in France — 11 open to participants now, 12 under way, 3 of them phase 3. Influenza, Human · France.

Planned enrollment
22nd of 79
735 · median 312
Started
2025
with 3 others
No phase
21 of 103
4 open now
Primary completion
2027-03
later than 4 of 11 live
Registered
99th of 103
by date
Lead sponsor
2 of 103
Centre Hospitalier Universitaire de Nice

Among the 103 studies in Influenza, Human with a site in France, this one is the 22nd largest by planned enrollment of the 79 interventional ones that give a count, is one of 4 that started in 2025, is one of 21 with no phase, reaches primary completion later than 4 of the 11 other live ones, and was the 99th registered.

Influenza, Human

2,361 studies on the registry are indexed under Influenza, Human; 186 are open to participants now.

Browse Influenza, Human studies →

Open to participants now

11 of the 103 studies in Influenza, Human with a site in France are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 124 Influenza, Human studies recruiting now, 67 (54%) set no upper age limit and 47 (38%) stop at 75 or younger; 34 take children under 18; 69 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 103 studies in Influenza, Human with a site in France, or all of them as a file.
02

Study summary

Immune response to influenza vaccine in patients with chronic renal insufficiency.

Read the detailed description

Seasonal influenza vaccination is recommended for patients with chronic renal insufficiency, as influenza is responsible for significant morbidity and mortality in this immunocompromised population. However, the immune response to this vaccination is limited in this population.

There are currently no recommendations concerning the timing of influenza vaccine in the general population or in immunocompromised patients.

In this context, recent studies have shown that the time of vaccination can have an impact on vaccine efficacy. This is the case for BCG, influenza and COVID vaccinations.

On this basis, our main hypothesis is that the administration of influenza vaccine to patients with chronic kidney failure is more effective in the morning than in the evening.

03

Conditions studied

  • Vaccination; Infection

Browse trials for

Keywords

  • Influenza
  • chronic renal insufficiency
  • Vaccination
04

In context

Influenza, Human Reclassified

2,361 studies on the registry are indexed under Influenza, Human; 186 are open to participants now.

This study's planned enrollment of 735 is above the median of 228 across 1,959 interventional studies indexed under Influenza, Human.

Browse Influenza, Human studies →

Lead sponsor

Centre Hospitalier Universitaire de Nice is the lead sponsor of 725 studies on the registry; 177 are open to participants now.

Compared within Influenza, Human, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Infections. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Chronic renal failure patient at stage 4 or 5 (i.e. estimated \< 30mL/min/1.73m2); or Dialysis patient; or renal transplant patient regardless of GFR;
  • Age ≥ 18 years;
  • Indication for influenza vaccination;
  • Express free and .

Exclusion criteria

Exclusion Criteria:

  • Known to influenza vaccine or egg proteins;
  • Previous influenza vaccination for the current season;
  • Current infection;
  • Current acute illness;
  • Treatments with a major impact on vaccine response:
  • Treatment of rejection within the previous 3 months;
  • Renal transplantation with induction performed within the previous 6 months;
  • treatment including CTLA4 agonist, complement inhibitor, anti-CD20;
  • Treatments that may distort the serological response: Polyvalent immunoglobulin infusion within the preceding 3 months;
  • Vulnerable persons (minors, adults under guardianship or trusteeship, persons deprived of their liberty, persons unable to speak French);
  • Subjects not affiliated to Social Security.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

06

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
735 participants (estimated)

Study arms

  • Active comparator
    Morning injection

    VAXIGRIPTETRA influenza vaccine injection between 07:00 am and 11:00 am.

    Other: Vaccine injection

  • Active comparator
    Evening injection

    VAXIGRIPTETRA influenza vaccine injection between 05:00 pm and 09:00 pm.

    Other: Vaccine injection

Interventions

  • OtherVaccine injection

    Injection of the vaccine in chronic renal insufficiency patients.

    Also known as: VAXIGRIPTETRA - quadrivalent inactivated influenza vaccine.

07

What researchers measure

Primary outcomes

  1. Antibody titers (seroconversion) at 4 weeks after injection of inactivated influenza vaccine in each arm.

    Seroconversion will be defined as an increase in antibody titer of at least 4-fold (≥4) over pre-vaccination titer AND an antibody titer ≥ 1:40 (seroprotection) four weeks post-vaccination, for at least one of the three vaccine antigens.

    Time frame: 7 months

Secondary outcomes

  1. Number of seasonal influenza virus infections in each arm at 4 weeks

    Comparing the number of seasonal influenza virus infections in each arm between a group of patients vaccinated in the morning and a group vaccinated in the evening at 4 weeks. The occurrence of influenza, as confirmed by a PCR test, will be noted in the follow-up consultation.

    Time frame: 7 months

  2. Number of seasonal influenza virus infections in patients with chronic renal insufficiency at 6 months

    Comparing the number of seasonal influenza virus infections in patients with chronic renal failure between a group of patients vaccinated in the morning and a group vaccinated in the evening in the 6 months following vaccination. The occurrence of influenza, as confirmed by a PCR test, will be noted in the follow-up consultation.

    Time frame: 12 months

  3. Antibody titers reacting in each arm

    In patients with chronic renal failure, compare the evolution of antibody titres reacting with vaccine antigens 4 weeks after influenza vaccination between a group of patients vaccinated in the morning and a group of patients vaccinated in the evening. The titer of antibodies reacting with vaccine antigens is measured by ELISA ;

    Time frame: 7 months

  4. Number of anti-vaccine antibodies inhibiting hemmagglutination

    4 weeks after influenza vaccine injection, compare hemmagglutination-inhibiting anti-vaccine antibody titer in CKD patients vaccinated in the morning and evening. The titer of hemagglutination-inhibiting anti-vaccine antibodies will be determined by hemagglutination inhibition test

    Time frame: 7 months

  5. Number of neutralizing anti-vaccine antibodies

    To compare, 4 weeks after influenza vaccine injection, the titer of neutralizing antivaccine antibodies in CKD patients vaccinated in the morning and evening. The titer of neutralizing anti-vaccine antibodies will be determined by a pseudo-neutralization test.

    Time frame: 7 months

08

Study locations

1 of 1 sites recruiting
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Mar 2027, 18 months after the start.

Of 147 non-industry interventional studies with no phase under Influenza, Human, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 18. This study's planned 18 months is above that.

Counting every sponsor, half of 167 studies reached it within 6 months; a quarter within 3 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 26, 2025
First posted
Apr 2, 2025
StartActual
Sep 3, 2025
Primary completionEst.
Mar 2027
CompletionEst.
Sep 2027
Last update
May 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06907667
Responsible party
Sponsor
First posted
Apr 2, 2025
Start date
Sep 3, 2025
Primary completion
Mar 2027 (estimated)
Completion
Sep 2027 (estimated)
Last update
May 15, 2026

Study contacts

GOSSET Clément, MD
Contact
gosset.c@chu-nice.fr
492038632 ext. +33
GOSSET Clément, MD
principal investigator · Centre Hospitalier Universitaire de Nice

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion